{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:40:38Z","timestamp":1787316038746,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Using a non-targeted metabolomics platform, we recently identified C-mannosyltryptophan and pseudouridine as non-traditional kidney function markers. The aims of this study were to obtain absolute concentrations of both metabolites in blood and urine from individuals with and without CKD to provide reference ranges and to assess their fractional excretions (FE), and to assess the agreement with their non-targeted counterparts. In individuals without\/with CKD, mean plasma and urine concentrations for C-mannosyltryptophan were 0.26\/0.72\u2009\u00b5mol\/L and 3.39\/4.30\u2009\u00b5mol\/mmol creatinine, respectively. The respective concentrations for pseudouridine were 2.89\/5.67\u2009\u00b5mol\/L and 39.7\/33.9\u2009\u00b5mol\/mmol creatinine. Median (25\n                    <jats:sup>th<\/jats:sup>\n                    , 75\n                    <jats:sup>th<\/jats:sup>\n                    percentiles) FEs were 70.8% (65.6%, 77.8%) for C-mannosyltryptophan and 76.0% (68.6%, 82.4%) for pseudouridine, indicating partial net reabsorption. Association analyses validated reported associations between single metabolites and eGFR. Targeted measurements of both metabolites agreed well with the non-targeted measurements, especially in urine. Agreement for composite nephrological measures FE and urinary metabolite-to-creatinine ratio was lower, but could be improved by replacing non-targeted creatinine measurements with a standard clinical creatinine test. In summary, targeted quantification and additional characterization in relevant populations are necessary steps in the translation of non-traditional biomarkers in nephrology from non-targeted discovery to clinical application.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-17107-5","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T06:06:31Z","timestamp":1512540391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["From Discovery to Translation: Characterization of C-Mannosyltryptophan and Pseudouridine as Markers of Kidney Function"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-447X","authenticated-orcid":false,"given":"Peggy","family":"Sekula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-2380","authenticated-orcid":false,"given":"Katja","family":"Dettmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska C.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Gronwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9315-9541","authenticated-orcid":false,"given":"Robert P.","family":"Mohney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9638-3912","authenticated-orcid":false,"given":"Karsten","family":"Suhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi","family":"Kastenm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Oefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4671-3714","authenticated-orcid":false,"given":"Anna","family":"K\u00f6ttgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,12]]},"reference":[{"key":"17107_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","volume":"382","author":"KU Eckardt","year":"2013","unstructured":"Eckardt, K. U. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet \n                           382, 158\u201369 (2013).","journal-title":"Lancet"},{"key":"17107_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med \n                           150, 604\u201312 (2009).","journal-title":"Ann Intern Med"},{"key":"17107_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker, L. A. et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med \n                           367, 20\u20139 (2012).","journal-title":"N Engl J Med"},{"key":"17107_CR4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens, L. A., Coresh, J., Greene, T. & Levey, A. S. Assessing kidney function\u2013measured and estimated glomerular filtration rate. N Engl J Med \n                           354, 2473\u201383 (2006).","journal-title":"N Engl J Med"},{"key":"17107_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1681\/ASN.2014111099","volume":"27","author":"P Sekula","year":"2016","unstructured":"Sekula, P. et al. A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. J Am Soc Nephrol \n                           27, 1175\u201388 (2016).","journal-title":"J Am Soc Nephrol"},{"key":"17107_CR6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/ki.2013.497","volume":"85","author":"MA Niewczas","year":"2014","unstructured":"Niewczas, M. A. et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int \n                           85, 1214\u201324 (2014).","journal-title":"Kidney Int"},{"key":"17107_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1210\/jc.2015-3345","volume":"101","author":"A Solini","year":"2016","unstructured":"Solini, A. et al. Prediction of Declining Renal Function and Albuminuria in Patients With Type 2 Diabetes by Metabolomics. J Clin Endocrinol Metab \n                           101, 696\u2013704 (2016).","journal-title":"J Clin Endocrinol Metab"},{"key":"17107_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.copbio.2012.10.003","volume":"24","author":"J Adamski","year":"2013","unstructured":"Adamski, J. & Suhre, K. Metabolomics platforms for genome wide association studies\u2013linking the genome to the metabolome. Curr Opin Biotechnol \n                           24, 39\u201347 (2013).","journal-title":"Curr Opin Biotechnol"},{"key":"17107_CR9","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/ac051632c","volume":"78","author":"F Dieterle","year":"2006","unstructured":"Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem \n                           78, 4281\u201390 (2006).","journal-title":"Anal Chem"},{"key":"17107_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1053\/j.ajkd.2012.01.014","volume":"60","author":"ON Goek","year":"2012","unstructured":"Goek, O. N. et al. Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis \n                           60, 197\u2013206 (2012).","journal-title":"Am J Kidney Dis"},{"key":"17107_CR11","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/ndt\/gft217","volume":"28","author":"ON Goek","year":"2013","unstructured":"Goek, O. N. et al. Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. Nephrol Dial Transplant \n                           28, 2131\u20138 (2013).","journal-title":"Nephrol Dial Transplant"},{"key":"17107_CR12","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1681\/ASN.2012101006","volume":"24","author":"EP Rhee","year":"2013","unstructured":"Rhee, E. P. et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol \n                           24, 1330\u20138 (2013).","journal-title":"J Am Soc Nephrol"},{"key":"17107_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000446484","volume":"43","author":"EP Rhee","year":"2016","unstructured":"Rhee, E. P. et al. Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study. Am J Nephrol \n                           43, 366\u201374 (2016).","journal-title":"Am J Nephrol"},{"key":"17107_CR14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/clinchem\/34.6.1011","volume":"34","author":"JT Bernert Jr.","year":"1988","unstructured":"Bernert, J. T. Jr., Bell, C. J., Guntupalli, J. & Hannon, W. H. Pseudouridine is unsuitable as an endogenous renal clearance marker. Clin Chem \n                           34, 1011\u20137 (1988).","journal-title":"Clin Chem"},{"key":"17107_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000186836","volume":"61","author":"R Dzurik","year":"1992","unstructured":"Dzurik, R., Lajdova, I., Spustova, V. & Opatrny, K. Jr. Pseudouridine excretion in healthy subjects and its accumulation in renal failure. Nephron \n                           61, 64\u20137 (1992).","journal-title":"Nephron"},{"key":"17107_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0002-9343(00)00693-8","volume":"110","author":"R Takahira","year":"2001","unstructured":"Takahira, R. et al. Tryptophan glycoconjugate as a novel marker of renal function. Am J Med \n                           110, 192\u20137 (2001).","journal-title":"Am J Med"},{"key":"17107_CR17","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/j.1523-1755.2004.00521.x","volume":"65","author":"K Yonemura","year":"2004","unstructured":"Yonemura, K., Takahira, R., Yonekawa, O., Wada, N. & Hishida, A. The diagnostic value of serum concentrations of 2-(alpha-mannopyranosyl)-L-tryptophan for normal renal function. Kidney Int \n                           65, 1395\u20139 (2004).","journal-title":"Kidney Int"},{"key":"17107_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0003-2697(83)90644-9","volume":"130","author":"A Colonna","year":"1983","unstructured":"Colonna, A., Russo, T., Esposito, F., Salvatore, F. & Cimino, F. Determination of pseudouridine and other nucleosides in human blood serum by high-performance liquid chromatography. Anal Biochem \n                           130, 19\u201326 (1983).","journal-title":"Anal Biochem"},{"issue":"Pt 1","key":"17107_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1042\/bj3430011","volume":"343","author":"B Gutsche","year":"1999","unstructured":"Gutsche, B., Grun, C., Scheutzow, D. & Herderich, M. Tryptophan glycoconjugates in food and human urine. Biochem J \n                           343(Pt 1), 11\u20139 (1999).","journal-title":"Biochem J"},{"key":"17107_CR20","doi-asserted-by":"publisher","first-page":"e13953","DOI":"10.1371\/journal.pone.0013953","volume":"5","author":"K Suhre","year":"2010","unstructured":"Suhre, K. et al. Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One \n                           5, e13953 (2010).","journal-title":"PLoS One"},{"key":"17107_CR21","doi-asserted-by":"publisher","first-page":"e16957","DOI":"10.1371\/journal.pone.0016957","volume":"6","author":"N Psychogios","year":"2011","unstructured":"Psychogios, N. et al. The human serum metabolome. PLoS One \n                           6, e16957 (2011).","journal-title":"PLoS One"},{"key":"17107_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/gm337","volume":"4","author":"R Mandal","year":"2012","unstructured":"Mandal, R. et al. Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update. Genome Med \n                           4, 38 (2012).","journal-title":"Genome Med"},{"key":"17107_CR23","doi-asserted-by":"publisher","first-page":"e1005487","DOI":"10.1371\/journal.pgen.1005487","volume":"11","author":"J Raffler","year":"2015","unstructured":"Raffler, J. et al. Genome-Wide Association Study with Targeted and Non-targeted NMR Metabolomics Identifies 15 Novel Loci of Urinary Human Metabolic Individuality. PLoS Genet \n                           11, e1005487 (2015).","journal-title":"PLoS Genet"},{"key":"17107_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.clinbiochem.2016.06.002","volume":"49","author":"J Klepacki","year":"2016","unstructured":"Klepacki, J. et al. Amino acids in a targeted versus a non-targeted metabolomics LC-MS\/MS assay. Are the results consistent? Clin Biochem \n                           49, 955\u201361 (2016).","journal-title":"Clin Biochem"},{"key":"17107_CR25","doi-asserted-by":"publisher","first-page":"e0153672","DOI":"10.1371\/journal.pone.0153672","volume":"11","author":"I Yet","year":"2016","unstructured":"Yet, I. et al. Genetic Influences on Metabolite Levels: A Comparison across Metabolomic Platforms. PLoS One \n                           11, e0153672 (2016).","journal-title":"PLoS One"},{"key":"17107_CR26","doi-asserted-by":"publisher","first-page":"E479","DOI":"10.1210\/jc.2013-3596","volume":"99","author":"DO Mook-Kanamori","year":"2014","unstructured":"Mook-Kanamori, D. O. et al. 1,5-Anhydroglucitol in saliva is a noninvasive marker of short-term glycemic control. J Clin Endocrinol Metab \n                           99, E479\u201383 (2014).","journal-title":"J Clin Endocrinol Metab"},{"key":"17107_CR27","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ndt\/gfr456","volume":"27","author":"KU Eckardt","year":"2012","unstructured":"Eckardt, K. U. et al. The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant \n                           27, 1454\u201360 (2012).","journal-title":"Nephrol Dial Transplant"},{"key":"17107_CR28","first-page":"559","volume":"180","author":"HU Prokosch","year":"2012","unstructured":"Prokosch, H. U. et al. Designing and implementing a biobanking IT framework for multiple research scenarios. Stud Health Technol Inform \n                           180, 559\u201363 (2012).","journal-title":"Stud Health Technol Inform"},{"key":"17107_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ndt\/gfu294","volume":"30","author":"S Titze","year":"2015","unstructured":"Titze, S. et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant \n                           30, 441\u201351 (2015).","journal-title":"Nephrol Dial Transplant"},{"key":"17107_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland, J. M. & Altman, D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet \n                           1, 307\u201310 (1986).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17107-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:59:40Z","timestamp":1671793180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-17107-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["17107"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-17107-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,12]]},"assertion":[{"value":"13 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RPM is employed by Metabolon, Inc. He contributed to the logistics and optimization of MS spectrometry and to MS data interpretation. Metabolon Inc. was not involved in the design of the study, statistical analysis or interpretation of the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"17400"}}